Purpose: To determine variations in cytokine levels of glaucoma patients treated either with preservative-free latanoprost or preserved latanoprost, relative to healthy individuals. Methods: Tear samples were collected from 39 healthy subjects, 20 glaucoma patients treated with preserved latanoprost, and 20 patients treated with preservative-free latanoprost.
Introduction
Glaucoma affects over 60 million people worldwide and is the second leading cause of blindness [1] . Elevated intraocular pressure (IOP) is the main risk factor for development of glaucoma. Thus, the goal of the current standard of care is to lower IOP levels. Following this rationale, different topical hypotensive compounds have emerged, including prostaglandin analogues (PGAs), carbonic anhydrase inhibitors, b-adrenergic receptor antagonists, a-2 selective adrenergic agonists, and non-selective adrenergic agonists. Remarkably, their high IOP-reducing efficacy places PGAs as one of the first-line treatments for glaucoma [2] .
In PGAs-based formulations, supplementation with preservatives to protect from microbial contamination entails several ocular side effects [3, 4] . The presence of benzalkonium chloride (BAK) in latanoprost, the most frequently prescribed PGA, is associated with conjunctival hyperemia, superficial punctate keratopathy, or squamous metaplasia [5e7]. Furthermore, long-term exposure to BAK-preserved medications may cause or aggravate pre-existing ocular surface diseases (OSDs), such as dry eye, blepharitis, meibomian gland dysfunction, chronic conjunctival inflammation, or corneal surface impairment [8, 9] . These ocular disorders result in eye irritation, blurred vision or tearing, and in a general deterioration of patients' quality of life [10] . To circumvent these detrimental effects, efforts have been made to develop preservative-free formulations for the management of glaucoma. Following this approach, preservative-free latanoprost was developed as a topical glaucoma treatment. Compared with its preserved counterpart, preservative-free latanoprost showed equivalent efficacy in reducing IOP, was better tolerated, and reduced the number of associated ocular adverse events, such as conjunctival hyperemia [11e13] . However, the mechanisms behind these favorable effects are not completely understood.
Inflammation is the key underlying mechanism fueling preservative-associated OSDs. Hypotensive eye drops induce the expression of several cytokines, including interleukins, interferon (IFN)-g, and tumor necrosis factor (TNF)-a [8, 14] . Therefore, cytokines have become reliable biomarkers for the diagnosis, monitoring, and classification of OSDs. Their increasing importance is evidenced by the number of tools applied to detect cytokines in tears, including proteomic techniques, enzyme-linked immunosorbent assay (ELISA), membrane microarrays, and multiplex bead assays [15] .
In this study, we compared the cytokine profile of patients treated either with preservative-free latanoprost (Monoprost ® ; Thea, Clermont-Ferrand, France) or preserved latanoprost (Xalatan ® ; Pfizer, New York, USA), by using multiplex bead technology. We evaluated changes in the concentration of 27 inflammatory cytokines in glaucoma patients, treated with or without preservatives, relative to healthy patients. To the best of our knowledge, this is the first study comparing the impact in cytokine concentration of long-term instillation with either preserved or preservative-free eye drops.
Material and methods

Participants
This prospective, observational study was conducted at the Hospital Clínico San Carlos (Madrid, Spain). A total of 79 subjects were prospectively recruited between December 2015 and April 2016. Glaucoma patients were receiving either Monoprost or Xalatan for periods ranging from 6 to 120 months. The study also enrolled 39 healthy age-and sex-matched controls.
The study adhered to the tenets of the Declaration of Helsinki and the Spanish legislation, and was approved by the local Institutional Clinical Research Ethics Committee. Written legallybinding informed consent was obtained from all participants before recruitment. Exclusion criteria included glaucoma surgery within the last six months, secondary glaucoma (including congenital, traumatic, steroid, uveitic, or angle closure), treatment with concomitant topical medications (such as lubricant eye-drops), any ocular surface disease that could have influenced treatment election, other serious eye disease or syndrome, or any physical or mental problem hindering the realization of tests or examinations required for the study.
Each patient was examined and medical history was recorded in a single visit. The information collected included demographic data, treatment duration, and the type (Monoprost or Xalatan) of eye drops received.
Tear collection
Tear samples were collected using a sterile microcapillary tube from a single eye of each individual. Samples were frozen at À80 C and stored until analysis. To avoid evaporation or degradation, the elapsed time between collection and storage was kept below 15 min. Since tear volumes ranged from 2 to 15 mL, saline buffer (Braun Mini-Plasco ® ) was added to each sample before storage to reach 50 mL (the minimum volume for analysis).
Cytokine quantification
Cytokine concentrations were determined in tear samples using Briefly, 50 mL of tear samples were dispensed into defined wells of the 96-microwell plate. Samples were simultaneously read on the Luminex MAGPIX reader (Luminex Corporation, Austin TX USA). Cytokine concentrations were derived by interpolating the measured fluorescence intensities to standard curves, and correcting by the corresponding dilution factor employed to achieve the minimum volume for analysis. Bio-Plex Manager™ software was employed to calculate cytokine concentrations.
Ocular surface measurements
The ocular surface parameters evaluated included corneal fluorescein staining, non-invasive tear breakup time (NI-TBUT), tear meniscus height, conjunctival hyperemia and ocular surface disease index (OSDI). These parameters were assessed at least 48 h before or after tear sample acquisition.
NI-TBUT and conjunctival hyperemia were measured by the Keratograph 5 (Oculus, Wetzlar, Germany), and the lower tear meniscus height was evaluated by the Spectralis Fourier-Domain OCT (Heidelberg Engineering GmbH, Germany) [19] .
All eyes were examined using a standard slit lamp at Â16 magnification. The cornea was stained using fluorescein staining (Minims-fluorescein sodium 2.0%; Chauvin Pharmaceuticals Ltd.). Corneal staining was graded using the 6-point Oxford scale (0 ¼ no staining; 5 ¼ severe staining). Since all the patients evaluated exhibited a maximum corneal staining score of 1, this variable was subsequently graded as negative or positive (score 0 or 1, respectively).
Global OSDI score was calculated for each participant from the following equation: 12.5 Â [(sum of individual question scores)/ (number of questions answered)], which yields a global score ranging from 0 to 100.
Statistical methods
Statistical analyses were performed using SAS software for Windows, version 9.2. To evaluate differences between study groups, quantitative variables were analyzed using the Student's ttest for independent samples, whereas categorical variables were compared using the Chi-square test. Spearman rank correlation was used to analyze the correlations between tear cytokine levels and ocular surface parameters. The adjusted level was established by Bonferroni test. p < 0.05 was the threshold to determine statistically significant differences.
Results
Demographic characteristics of study groups
Demographic characteristics of the participants are listed in Table 1 . A total of 79 subjects (median age, 70 years; range, 29e88 years) participated in this study; 34 were males (43.0%) and 45 were females (57.0%). The study enrolled 40 glaucoma patients, and 39 individuals with no history of ocular disease were enrolled as untreated controls. Among glaucoma patients, 20 were receiving Monoprost and the other 20 Xalatan as topical anti-glaucoma medication. Mean time of treatment did not statistically differ between the two groups (29.6 ± 27.2 months for Monoprost and 33.8 ± 26.5 months for Xalatan; p ¼ 0.619). The demographic variables assessed were not significantly different between groups (p > 0.05).
Effects of Xalatan on tear cytokine levels
A set of 27 relevant inflammatory cytokines were analyzed in Xalatan-treated and control tears. The absolute concentration of each cytokine is presented in Table 2 . Cytokine levels were systematically greater in patients receiving Xalatan, compared to healthy participants (Fig. 1) . Among all the cytokines evaluated, there was a significant increase (p < 0.05) in the levels of IL-2, IL-5, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, FGF basic, PDGF-BB, and TNF-a in Xalatan-treated versus control subjects. Remarkably, PDGF-BB and TNF-a showed the highest increase in concentration (1.9-fold) in patients treated with Xalatan, relative to normal subjects.
Effects of Monoprost on tear cytokine levels
Cytokine concentrations in Monoprost-treated and control tears are given in Table 3 . Levels of cytokines were highly coincident for Monoprost and control groups (Fig. 1) . Likewise, changes in cytokine concentrations between patients receiving Monoprost and healthy subjects failed to reach statistical significance for all the 27 cytokines studied (p > 0.05). Remarkably, those cytokines with significantly increased levels in the previous comparison (Xalatan versus control), remained statistically invariable when Monoprosttreated patients were compared with healthy patients. 
Cytokine profiles and clinical parameters in Monoprost and Xalatan groups
The comparison of Xalatan-and Monoprost-treated tears revealed that, except for IP-10, all the cytokines evaluated were higher in the Xalatan group, with the levels of IL-2, IL-15, IL-17 and TNF-a reaching statistical significance (p < 0.05) ( Table 4 , Fig. 1 ).
Clinical parameters of ocular surface showed similar levels in both Monoprost and Xalatan groups. Concretely, tear meniscus height, OSDI, NI-TBUT, and conjunctival hyperemia were statistically equivalent in Monoprost-and Xalatan-treated patients (p > 0.05) ( Table 5 ). Corneal fluorescein staining and the presence of epitheliopathy were not significantly different between Monoprost and Xalatan groups (p ¼ 0.491). No significant correlation was observed between cytokine levels and clinical parameters of ocular surface disease (OSDI, NI-TBUT, conjunctival hyperemia, and tear meniscus height), when analyzing those cytokines with significantly different levels in Monoprost and Xalatan groups (IL-2, IL-15, IL-17 and TNF-a).
Discussion
Due to the chronic nature of glaucoma, many glaucomatous patients require lifetime treatment. The current goal of antiglaucoma therapy is to lower IOP without compromising patients' quality of life [10, 20] . The use of PGAs as topical medication entails several adverse events, which often derive from the presence of preservatives in these ophthalmic preparations [21, 22] . Adverse events include inflammation or corneal impairment, among other symptoms of discomfort, and can result in treatment discontinuation [23e25]. In this regard, there is increasing concern about the risks associated with the use of preservatives in anti-glaucoma medications.
For this reason, developing new anti-glaucoma formulations without preservatives appears to be a successful therapeutic avenue for the management of glaucoma. Different preservativefree PGAs are currently available that are no less effective in reducing IOP than their preserved counterparts [26e28]. Furthermore, switching studies revealed that changing from preserved to preservative-free medications significantly improved signs and symptoms related to OSDs [29, 30] .
Among PGAs, we focused on latanoprost, the most frequently prescribed formulation, because of its high tolerability and the lesser number of side effects associated with its use [7] . Despite its potency, various adverse events have been associated with the presence of BAK in latanoprost formulation [5e7]. Preservative-free latanoprost (Monoprost) was therefore conceived to maintain the drug potency of latanoprost while reducing the associated adverse events.
A variety of studies support the advantages of Monoprost as topical anti-glaucoma medication. In an in vivo study, Pauly and colleagues revealed that epithelial cell viability was higher after treatment with preservative-free latanoprost compared to Data are expressed as mean (pg/mL) ± SD. Statistical significance between groups was determined using the Student's t-test. *Indicates a statistically significant difference (p < 0.05). Abbreviations: IL ¼ interleukin; FGF ¼ fibroblast growth factor; G-CSF ¼ granulocyte colony stimulating factor; GM-CSF ¼ granulocyte monocyte colony stimulating factor; IFN ¼ interferon; IP ¼ interferon gamma-induced protein; MCP1(MCAF) ¼ monocyte chemo attractant protein; MIP ¼ macrophage inflammatory protein; PDGF ¼ platelet-derived growth factor; RANTES ¼ regulated on activation, normal T cell expressed and secreted; TNF ¼ tumor necrosis factor; VEGF ¼ vascular endothelial growth factor; SD ¼ standard deviation. treatment with preserved latanoprost [11] . A randomized, multinational trial demonstrated equivalent efficacy between preserved and preservative-free latanoprost in reducing IOP levels [12] . A meta-analysis of randomized clinical trials confirmed that preservative-free latanoprost presented equivalent safety and reduced adverse events, such as conjunctival hyperemia, compared to preserved latanoprost [31] . A phase 2 study reported no differences between latanoprost with or without preservative, in terms of safety and patient tolerance [32] . Additionally, commercialization in single-dose format ensures Monoprost sterility. Several studies have revealed important differences between preserved and preservative-free latanoprost, but none has directly compared their impact on tear cytokine levels. Inflammation is a key cause and effect of the onset and progression of OSDs, which can be reliably monitored by measuring cytokine levels. In this study, we compared differences in cytokine concentrations promoted either by Monoprost or Xalatan in glaucoma patients. We observed that treatment with Xalatan resulted in great variations of cytokine levels in tears. However, and interestingly, upon treatment with Monoprost, we only observed mild changes that did not reach statistical significance.
We simultaneously determined the concentration of 27 cytokines employing multiplex technology, thus eliminating inter-assay variability. The cytokine profile of patients treated with Xalatan revealed a significant increase in IL-2, IL-5, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, FGF basic, PDFG-BB, and TNF-a. Among them, PDFG-BB and TNF-a showed the highest increase in concentration (1.9-fold) in patients treated with Xalatan, whereas their expression was statistically unchanged in patients treated with Monoprost. TNF-a is a pleiotropic protein eliciting different cellular responses, such as apoptotic cell death or inflammation [33] . Consistently, both apoptosis and inflammation participate in ocular adverse events associated with the use of preservatives in ophthalmic preparations. Indeed, BAK is able to interact with cell death receptors, inducing apoptosis and inflammation [34, 35] . This fact, together with the elevated levels of TNF-a in patients treated with Xalatan, suggests that apoptosis could also play a role in these associated side effects. In addition to playing this role, TNF-a is a recognized marker of dry eye disease [18, 36] . In line with this, growth factors such as PDGF-BB and FGF basic play a critical role in the maintenance of corneal function and imbalances in their expression are found in different ocular pathologies [37, 38] . In addition, IL-17 (the IL presenting the highest increase) is also associated with the severity of different OSDs, such as uveitis, scleritis and dry eye disease [39e41]. Overall, patients treated with Xalatan presented an increased expression of different OSD markers, which could indicate that they are more prone to suffer or exacerbate these ophthalmic pathologies.
Nevertheless, other relevant markers of OSDs, such as IL-b1 or IL-6, are not differentially expressed in patients treated with Xalatan [42] . This apparent discrepancy could be explained considering that early and late inflammatory responses greatly differ in their cytokine profile. In this regard, this study was conducted in individuals already under treatment for long-term periods (ranging from 6 to 120 months). This fact represents an important strength of our study, since it reflects the actual context of patients chronically exposed to anti-glaucoma treatments. In contrast, clinical trials are usually performed according to shortterm schedules, thus underestimating potential long-term effects. Unexpectedly, no relevant differences in ocular surface measurements (corneal staining, conjunctival hyperemia, NI-TBUT, and tear meniscus height) were observed between Xalatan-and Monoprosttreated patients. In addition, cytokine levels and these ocular surface parameters were not statistically correlated in either the Xalatan or the Monoprost groups. Thus, although the presence of BAK is not apparently influencing these ocular surface markers, it could be impacting other clinical outcomes, such as the success of posterior glaucoma surgery. The lack of correlation indicates that the inflammatory status achieved after long-term treatment with either Monoprost or Xalatan is not directly translated in detectable differences by exploratory procedures. This fact could be explained considering the wide variation of treatment durations that could compensate potential differences in clinical measurements between both groups. This idea is in accordance with previous studies in which transition from latanoprost to BAK-free tavoprost showed that hyperemia was not significantly altered at 1 month, but it was significantly decreased after 3e12 months of treatment [43] . Hence, it would be interesting to unveil the inflammatory profile of patients as a function of treatment duration, to distinguish between acute and chronic adverse events derived from the use of preservatives, and to establish its potential correlation with ocular surface markers.
A limitation of this study is that basal levels of cytokines were not determined before treatment initiation. However, since patient selection was not based on clinical characteristics or previous treatment intolerances, we can assume that cytokine levels were balanced between both groups. Further studies should be conducted using a crossover design switching from preserved to preservative-free latanoprost, and vice versa. By quantifying cytokine levels before and after each treatment course, we could rule out any baseline effect.
Taken together, the results of this study support previous reports of the beneficial effects of Monoprost in patients, and highlights the importance of assessing the cytokine profile to characterize inflammatory effects of topical medications.
Conclusions
This study compared the cytokine profile of patients treated with preservative-free or preserved latanoprost. The lack of inflammation associated with preservative-free latanoprost treatment is likely responsible for its significant reduction of adverse events. These findings may have special relevance for patients receiving long-term treatment, and with OSDs.
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